semaglutide mecanismo de accion Agonista del receptor GLP 1: acción Enfoque terapéutico de la diabetes
Description
Ozempic in these studies compared favourably with other treatments, sitagliptin, exenatide and insulin glargine (which led to reductions of 0.55, 0.92, 0.83 percentage points respectively) and placebo (reductions of up to 0.09 percentage points)
Studies involving semaglutide or liraglutide should also rule out pregnant or breastfeeding subjects, as their use in these conditions has not been extensively studied [16]
Hansen HH, Fabricius K, Barkholt P, Kongsbak-Wismann P, Schlumberger C, Jelsing J, et al
J Am Coll Cardiol 2020;76:961-984
From our offices, we represent clients nationwide in pharmaceutical lawsuits, including those against the makers of Ozempic
